<DOC>
	<DOCNO>NCT01455597</DOCNO>
	<brief_summary>This open-label extension study evaluate long-term safety efficacy WC3011 non-hysterectomized , healthy , postmenopausal woman vulvovaginal atrophy .</brief_summary>
	<brief_title>Evaluate Long-Term Safety Efficacy WC3011</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Completed Study PR04409 Developed follow StudyPR04409 begin take hormone therapy WC3011 : Hypersensitivity estrogen and/or progestin therapy Known suspect premalignant malignant disease ( except successfully treat skin cancer ) Manifestation treatment significant cardiovascular disease , stroke ischemic attack Insulindependent diabetes mellitus Smoking ≥ 15 cigarette daily Uncontrolled hypertension systolic blood pressure ( BP ) ≥ 160 mmHG diastolic ≥ 95 mmHg</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Postmenopausal Women</keyword>
	<keyword>Vaginal Dryness</keyword>
	<keyword>Postmenopausal Vulvovaginal Atrophy</keyword>
</DOC>